Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.02 | 0.14 | -2.80 | 0.71 |
| FCF Yield | 2.29% | -0.23% | 2.86% | 0.07% |
| EV / EBITDA | 67.78 | 51.38 | 82.20 | 210.93 |
| Quality | ||||
| ROIC | 0.28% | 0.54% | 0.13% | -0.83% |
| Gross Margin | 52.98% | 50.83% | 49.66% | 40.33% |
| Cash Conversion Ratio | 2.93 | 1.53 | 5.56 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.88% | 2.55% | 1.46% | -0.19% |
| Free Cash Flow Growth | 1,121.57% | -108.77% | 4,241.91% | -98.06% |
| Safety | ||||
| Net Debt / EBITDA | -20.09 | -16.54 | -19.26 | -20.12 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.38 | 0.36 | 0.36 | 0.46 |
| Cash Conversion Cycle | 282.69 | 322.54 | 337.26 | 298.39 |